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Abstract
Rifampicin, an important drug in the treatment of tuberculosis, is used extensively despite its broad
effects on drug-drug interactions, creating serious problems. The clinical importance of such
interactions includes autoinduction leading to suboptimal or failed treatment. The concomitantly
administered effects of rifampicin on other drugs can result in their altered metabolism or
transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the
gastrointestinal tract and liver. This review paper summarises recent findings with emphases on the
molecular mechanisms used to explain these broad drug-drug interactions. In general, rifampicin
can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects
cytochromes P450, glucuronosyltransferases and p-glycoprotein activities. This pattern of action
may explain many of the rifampicin inducing drug-drug interactions. However, effects through other
mechanisms have also been reported and these make any explanation of such drug-drug
interactions more complex.
Introduction
Multiple drug therapy is often used with a single patient.
For example, in individuals infected with HIV and tuber-
culosis, both anti-tuberculosis and antiretroviral agents
have to be used [1]. During treatment, drug-drug interac-
tions occur when the presence of one drug affects the bio-
availability of another through absorption, metabolism
or disposition, and therefore affects the treatment and
drug toxicity in the patient. The estimated incidence of
drug-drug interactions that have a clinical significance
ranges from 3% to 20%, depending on how many drugs
are taken [2]. These adverse reactions are sometimes life-
threatening. Such adverse effects caused by drug-drug
interactions could be eliminated by more rational drug
use, in which patients receive their medications in appro-
priate doses [3]. To achieve this use, an understanding of
the mechanism of drug-drug interactions is important, so
that dosages can then be adjusted correspondingly.
Rifampicin is an effective antibiotic against gram-positive
bacteria including mycobacteria, being frequently used
currently in the chemotherapy of tuberculosis along with
isoniazid, pyrazinamide and ethambutol/streptomycin
[4,5]. Most patients can be cured with this, but some
present with suboptimal or failed treatment [6,7]. Such
failures could, in part, be explained by well known autoin-
duction leading to decreased drug efficacy whereby the
drug stimulates its own metabolism into inactive metabo-
lites and thus loses its effectiveness [8,9]. Suboptimal or
failed treatment may also be arise from interactions with
other drugs and foodstuffs that affect the metabolism of
rifampicin [9-11]. For example, Trikatu, a commonly used
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herb in Ayurvedic medicine, can significantly reduce the
peak concentration of rifampicin probably by slowing
stomach emptying and gastrointestinal motility [12]. In
addition, rifampicin may also interfere with the metabo-
lism of other concomitantly administered drugs [13].
Thus, rifampicin has been used extensively in clinical
studies as a prototypical inducer of drug-metabolizing
enzymes and transporters, due not only to autoinduction
by itself or induction by other drugs and foodstuffs, but
also its broad effects on drug-drug interactions. Many ear-
lier reviews have discussed different aspects of rifampicin
metabolism and its effects on the actions of other drugs
[13-20]. However; application of molecular biology tech-
niques has led to a rapid accumulation of new knowledge.
Nuclear pregnane X receptor (PXR) and constitutive
androstane receptor (CAR) have now been discovered and
their roles in rifampicin-mediated drug-drug interactions
demonstrated [21-28]. Another important protein, p-glyc-
oprotein, has also been shown to interplay with CYP3A4
in rifampicin inducing drug-drug interactions [29]. This
paper reviews these recent findings, focusing on the
molecular mechanisms of rifampicin-inducing drug
metabolism.
History of rifampicin-inducing drug-drug interactions
Rifampicin-inducing drug-drug interactions were
recorded 25 years ago, and those affected include antico-
agulants, hypoglycaemia agents and contraceptives [30-
32]. The average elimination half-life of hexobarbital was
decreased from 624 to 262 min and that of tolbutamide
from 292 to 160 min following rifampicin treatment in
patients with cirrhosis or cholestasis [31]. Rifampicin at
600 mg/day caused about a 3 fold increase in pro-
pranolol's clearance [33]. During concurrent treatment
with prednisolone, rifampicin increased the plasma clear-
ance of prednisolone by 45% and reduced areas under
curves (AUC) by 66%, and these interactions have been
reviewed recently [19,34].
The rifampicin-inducing drug-drug interactions were first
discovered by Remmer (1972) to be caused by increased
levels of cytochrome P450 (CYP), a large group of heme-
containing monoxygenase isoenzymes encoded by a gene
superfamily [35-37]. Total human CYP was markedly
increased by rifampicin in needle biopsy samples taken
from human liver. It was found that concomitant admin-
istration of rifampicin and oral contraceptives could lead
to failure of the antifertility effect of the latter [38]. Further
studies elucidated the interaction to be caused by
increased estradiol metabolism [39,40]. Increased metab-
olism of estrodiol in the presence of rifampicin was
caused by the induction of estrogen-2-hydroxylation,
which is catalysed mainly by CYP1A2 and also CYP1A1,
CYP1B1 and CYP3A4 [41-43]. So far, many different CYPs
have been identified. Thus, each individual CYP is
assigned to a family, subfamily and number, so CYP1A2
stands for family 1, subfamily A, and isoform 2 [36].
Within the same family, all CYP proteins share at least 40
% sequence identity in their amino acid sequence, and
within the same subfamily, at least 55% [37].
In 1998, a member of the nuclear receptor superfamily-
PXR was found and named, based on its activation by
both natural and synthetic C21 steroids (pregnanes) [15-
17]. PXR was related to CYP3A4 and both are highly coex-
pressed in the liver and intestine. PXR is also activated by
CYP3A4 inducers including drugs such as rifampicin, dex-
amethasone, indinavir, paclitaxel, pesticides such as trans-
nonachlor, chlordane, endocrine disruptors such as
phthalic acid, nonylphenol and other environmental con-
taminants such as polychlorinated biphenols [21]. Fur-
ther experiments have demonstrated that PXR
Target genes activated by rifampicin via PXR and CAR Figure 1
Target genes activated by rifampicin via PXR and CAR. 
Rifampicin (Rif) induces nuclear receptors PXR and CAR that 
in turn activate a set of target genes including phase I 
enzymes such as CYP2B6, CYP2C8, CYP2C9 and CYP3A4, 
and phase II enzymes such as UGTs, GSTs and phase III 
enzymes such as p-glycoprotein. PXR and CAR are also regu-
lated by HNF4α and these target genes are also regulated by 
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transcriptionally regulates CYP3A4. Thus, PXR can bind to
CYP3A4 promoters to activate reporter genes, a process
that is disregulated in PXR-null mice [19,44].
In addition to CYP3A4, PXR also upregulates a large
number of genes involved in xenobiotic detoxification,
including enzymes of phase I, II and III drug metabolism
(Fig 1). These have been characterised by gene profiling
studies performed with pregnenolone 16α-carbonitrile in
wild-type and PXR-null mice [45]. The genes regulated by
PXR include those encoding CYP enzymes, p-glycopro-
tein, aldehyde dehydrogenases, UDP-glucuronosyltrans-
ferases (UGTs), sulfonyltransferases and glutathione-S-
transferases (GSTs).
Mechanism of induction of rifampicin- role of PXR
The mechanism of rifampicin-mediated induction of CYP
enzymes is now better understood. As mentioned earlier,
this induction is mediated by the activation of PXR, which
functions as a ligand-activated transcription factor
[21,22]. Thus, when a PXR ligand binds to PXR, it in turn
activates transcription of CYP 3A4 and several other genes
(Fig 2).
The mechanism of PXR in regulating CYP3A4 involves it
binding to response elements of the CYP3A4 gene that
confers transactivation. PXR binds to CYP3A promoters
together with the 9-cis retinoic acid receptor (RXR) as a
heterodimer to ER6 (everted repeat with a 6 bp spacer)
elements [25,46]. In the CYP3A4 gene, two PXR elements
(distant and proximal) have been identified that are sepa-
rated by more than 7000 nucleotides. Disruption of the
distant and proximal elements causes a 73% and 53%
decrease in the respective reporter activities. However, in
vitro binding studies showed that the proximal element
was preferred [42]. Chromatin immunoprecipitation
experiments showed that the genomic fragment harbour-
ing the proximal element was preferably precipitated over
the fragment containing the distant element in the
CYP3A4 gene [47]. The fact that CYP3A4 is disregulated in
PXR-null mice further demonstrates a role for PXR in
CYP3A4 activation [44].
Thus, rifampicin has been clearly identified as a PXR acti-
vator by binding to PXR [48]. It also modulates PXR bind-
ing to PXR elements of the CYP3A4 promoter [47].
Studies by X-ray crystallography indicated the overall
architecture of PXR binding to rifampicin comprised 12 α-
helices that fold to form a hydrophobic pocket in the
lower portion of the protein [20]. The large volume of the
PXR ligand-binding pocket characterised by a smooth,
elliptical shape explains why PXR acts as a broad-specifi-
city sensor of lipophilic xenobiotics.
Another receptor, constitutive androstane receptor (CAR),
is also involved in CYP3A4 transcriptional regulation.
CAR is a member of the steroid/retinoid/thyroid hormone
receptor superfamily. It has been demonstrated that CAR
can trans-activate CYP3A4 gene expression both in vitro
and  in vivo [49]. The CAR response elements are also
bound by PXR, indicating their interplay in CYP3A4
expression.
Transcriptional activation of rifampicin target genes Figure 2
Transcriptional activation of rifampicin target genes. Pregnane X receptor (PXR) binds with rifampicin in the cytoplasm and 
enters into nucleus to form a heterodimer with retinoic acid receptor (RXR). The heterodimer binds to the promoter of a tar-
get gene to activate the transcription of its open reading frame (ORF).Annals of Clinical Microbiology and Antimicrobials 2006, 5:3 http://www.ann-clinmicrob.com/content/5/1/3
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CAR has been demonstrated to cross-talk with PXR, i.e.
they share some ligands capable of binding to each other's
DNA response elements [44,45,49]. It was also confirmed
in chimeric mice with humanized mice liver in which
both human CYP3A4 mRNA and protein production was
dramatically increased by rifampicin [50]. In receptor-null
mice, PXR and CAR regulate overlapping but distinct sets
of genes [45]. The significance of cross-talk could be that
CAR and PXR together compensate for the loss or mal-
function of each other to a certain extent. However,
rifampicin has a much lower effect on CAR than PXR [45].
Effect of rifampicin on CYPs through PXR
CYPs are mainly found on the smooth endoplasmic retic-
ulum membranes in liver hepatocytes and along the intes-
tinal tract mucosal surface [51]. CYPs play an important
role in protecting organisms from potentially toxic com-
pounds, by their ability to biotransform lipophilic sub-
strates of diverse structures into more water-soluble
metabolites that are subsequently excreted from the body
[37,52]. They are also essential for eukaryotic life because
of their roles in the metabolism of sterols such as choles-
terol, bile acids, fatty acids, prostaglandins, leukotrienes,
retinoids as well as biogenic amines [51,53].
These CYPs are important in drug metabolism as they cat-
alyse metabolic reactions involving thousands of sub-
strates in over 60 different types of reactions [54].
Rifampicin can induce many CYPs including CYP2A,
CYP2B, CYP2C and CYP3A [51]. Among the many differ-
ent subsets of these enzymes, CYP3A4 is the most abun-
dant, in both the liver and the intestinal tract. CYP3A4 is
responsible for the oxidative metabolism of a wide variety
of substrates, involving steroid catabolism and metabo-
lism of foreign compounds, with many of the clinically
used drugs being substrates for CYP3A4. It is also a key
enzyme in chemical carcinogenesis in both the liver and
extrahepatic tissues [55].
The reactions catalysed by CYP3A4 include N-oxidation,
C-oxidation, N-dealkylation, O-dealkylation, nitro-reduc-
tion, dehydration and C-hydroxylation [55]. CYP3A4 is
the primary catalyst of steroid 6β-hydroxylation [56].
These broad reactions are explained by the structure of the
CYP3A4 active site which recently has been characterised
by X-ray crystallography [57].
CYP3A4 is more efficiently induced than other CYPs
[51,58-60]. In primary human hepatocytes, 20 microM
rifampicin increased CYP3A4 mRNA by 14 fold, but
CYP2B6 by only 2.1 fold [61]. CYP3A4 appears to be reg-
ulated transcriptionally by a variety of structurally diverse
compounds and hormones [46,62]. In cultured hepato-
cytes, triiodothyronine decreased CYP3A4 enzyme activity
as well as protein and mRNA levels, while dexamethasone
and growth hormone increased CYP3A4 gene expression
[63].
Rifampicin is involved in drug-drug interaction by its
induction of CYPs, especially CYP3A4, and CYP3A4
mRNA is induced by rifampicin in blood mononuclear
and liver HepG2 cells [64-66]. The CYP3A4 gene has also
been isolated and cloned. A 20-bp region residing -150 bp
upstream of the transcription initiation site has been
shown to confer responsiveness to rifampicin [67]. The
relative potency in inducing CYP3A4 by the rifamycins is
rifampicin > rifapentine > rifabutin [10].
Rifampicin can induce both gut (enterocytic) and liver
(hepatic) CYP, especially CYP3A4, and increase its own
metabolism (autoinduction), but the induced metabolic
pathway is still not clear [27]. In healthy volunteers,
repeated oral administration of rifabutin (450 mg daily
for 10 days) led to lower AUC and minimal blood concen-
tration (Cmin) values, compared to the corresponding
theoretical values, with an unchanged half-life [26]. This
indicates induced metabolism, although it is unclear as to
which specific enzymes are involved. Rifabutin, its deriva-
tives and metabolites, are likely to be metabolised by
CYPs, particularly by CYP3A4 [29,68]. If CYPs are
involved in rifampicin metabolism, how they act is not
clear [29].
There are marked individual variations in the expression
of CYP that affect the biological response (efficacy and/or
toxicity) of many drugs as well as individual responses to
CYP inducers [62,69]. In humans, a 10-fold variation
exists among individuals for rifampicin inducing CYP3A4
expression [70,71]. In the liver, substantial interindivid-
ual differences in CYP3A4 expression have been detected
that could not be explained by environmental factors
[70]. A similar situation was found in the intestine
whereby CYP3A4 mRNA levels in biopsies of mucosa of
five healthy subjects varied by about 10 fold [71]. These
differences could in part account for interpatient differ-
ences in the oral bioavailability of CYP3A4 substrates.
It has been well demonstrated that rifampicin-induced
CYP2C9 is mediated by PXR [72]. Deletion and mutagen-
esis studies showed that the functional PXR-responsive
element is located between -1839/-1824 base pairs
upstream from the translation start site previously identi-
fied to be CAR-responsive element, and essential for
rifampicin inducibility. A second CAR- responsive ele-
ment located at -2899/-2883 also has a cooperative effect.
In addition, PXR and CAR activate CYP2B6 by transcrip-
tional regulation, although not all CYP2B6 inducers acti-
vate PXR [73]. A phenobarbital-responsive enhancer
module (PBREM) has been identified, although forAnnals of Clinical Microbiology and Antimicrobials 2006, 5:3 http://www.ann-clinmicrob.com/content/5/1/3
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human CYP2B6, PBREM effects only a weak response to
PXR and CAR. A novel nuclear receptor response module
that strongly binds to both PXR and CAR has been
described and is known as the xenobiotic-responsive
enhancer module (XRE) [74].
Effect of rifampicin on glucuronosyltransferases through 
PXR
Rifampicin can induce UDP-glucuronosyltransferase 1A
(UGT1A) that catalyses the glucuronidation of a wide
range of xenobiotics and endogenous substrates
[48,75,76]. UGT1A is regulated by many factors in a tis-
sue-specific manner [77,78]. Both PXR and CAR mediate
expression of UGT1A [79-81]. Transgenic mice expressing
a constitutively active form of human PXR show a mark-
edly increase of UGT activity [79]. A XRE in the UGT1A
gene was thought to be responsible for this induction
[80]. The rifampicin mediated-UGT increase may lead to
increased clearance of steroids, heme, environmental tox-
ins and drugs [79].
Effect of rifampicin on p-glycoprotein through PXR
Studies in humans have long indicated that drug trans-
porters are involved in rifampicin hepatic and intestinal
uptake. p-Glycoprotein is a plasma membrane-bound
drug efflux (multidrug resistance pump), a 170 kDa phos-
phorylated and glycosylated protein, 1280 amino acids
long, which consists of two homologous halves of 610
amino acids joined by a flexible 60 amino acid linker [82].
p-Glycoprotein belongs to the ATP binding cassette super-
family of transport proteins encoded by the multidrug
resistance genes (MDR) and was found primarily in drug-
eliminating organs, including the kidney, liver, brain,
intestinal lumen, testes, adrenal gland, pregnant uterus,
tumour cells and epithelial cells [83,84]. They play an
important role in drug absorption and disposition, as a
biological barrier by extruding toxins and xenobitics from
cells rather than by enhancing the excretion of drugs from
hepatocytes and renal tubules. Human p-glycoprotein
plays an important role in drug efflux through these barri-
ers. Recent paired human tissue studies have shown p-
glycoprotein and CYP3A4 protein contents in intestine
were higher than in liver, which might indicate an impor-
tant role for the intestine in drug metabolisms [85].
Should the p-glycoprotein be induced by rifampicin, for
example, then the drug's therapeutic usefulness will
decline as more drugs are pumped out of the cells. p-Glyc-
oprotein has only recently been identified and thus the
potential risk of p-glycoprotein-mediated drug interac-
tions has probably been underestimated in the past. Many
drug interactions have been shown to involve both p-glyc-
oprotein and CYP3A4 due to overlapping substrate specif-
icity between them, and similarities in their inhibitors and
inducers, as for example, with the coinduction of CYP3A4
and p-glycoprotein by rifampin in human LS180 colon
carcinoma cells [86]. Furthermore, p-glycoprotein can
control drug access to intracellular CYP3A4 through
repeated cycles of drug absorption and efflux, as demon-
strated by the studies with cyclosporine, a p-glycoprotein
and CYP3A4 inhibitor and GG918, a p-glycoprotein
inhibitor only [23]. After inhibition of GG918, K77, a
substrate for p-glycoprotein and CYP3A4, accumulated in
the cell and metabolism was increased, but felodipine, a
substrate of CYP3A4 but not p-glycoprotein was not
changed [23]. Cyclosporine decreased the metabolisms of
both K77 and felodipine. In another study, inhibition of
p-glycoprotein increased both intestinal uptake and
blood concentrations of verapamil but with no changes in
its rate of metabolism [87].
Rifampicin both induces p-glycoprotein expression and
reduces digoxin concentrations during concomitant ther-
apy [88,89]. In healthy volunteers, oral administration of
digoxin with rifampicin showed lower plasma concentra-
tions than in those without. This was less pronounced if
digoxin was given intravenously. Correspondingly, p-glyc-
oprotein content was 3.5 fold higher after rifampicin
treatment [88]. Any regulation is likely to take place at the
transcriptional level since increased mRNA levels were
detected [90-92]. In healthy subjects, administration of
600mg rifampicin for 9 days upregulated p-glycoprotein
mRNA synthesis [92].
The induction of MDR1, a gene encoding p-glycoprotein,
is also activated by PXR which binds to PXR response ele-
ments located upstream of the MDR1 gene [93]. Only one
DR4 (direct repeat with a 4 bp spacer) motif (at about -8
kilobase pairs) was shown to be necessary for the induc-
tion by rifampicin, although several other binding sites
were identified. It has been demonstrated in mouse
hepatoma cell culture and rats that dexamethasone
induces the expression of MDR1 and MDR3, with two
genes encoding for p-glycoprotein in the mouse [94,95].
Other factors
PXR is also regulated by a hepatic nuclear factor
4α(HNF4α), which regulates many genes preferentially
expressed in liver [22]. HNF4α is stimulated by hepatic
maturation factors, such as oncostatin and matrigel, and
plays an important role in early embryogenesis [96]. In a
fetal hepatocyte primary culture system, inactivation of
HNF4α by infection with an adenovirus containing the
Cre gene leads to suppression of PXR [97]. An HNF4α
antisense RNA has been transducted into human hepato-
cytes, which resulted in the reduction of HNF4α protein
and CYP3A4 [98].
An HNF4α binding site has been characterised in the PXR
promoter that is necessary for expression of PXR in fetalA
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Table 1: Example drugs affected by rifampicin through different mechanisms
Mediated 
proteins
p-glycoprotein CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP3A4
Affected 
drugs
Anesthetics: Ropivacaine [118] Cyclophosphamine [74] Alfentanyl [13]
Ropivacaine [118]
Analgesics: Mexiletine [119] Codeine [19]
Dapsone [19]
Anti-arrhythmics: Mexiletine [119]
Propafenone [120]
Quinidine [19]
Anti-cancer drugs: Cyclophosphamide [74]
Ifosfamide [74]
Cyclophosphamide [74]
Ifosfamide [74]
Cyclophosphamide [74] Cyclophosphamide [74]
Imatinib [121]
Tamoxifen [19]
Anti-epileptics: Mephenytoin [122]
Anti-histamines: Fexofenadine [123]
Terfenadine [123]
Fexofenadine [123]
Terfenidine [123]
Anti-microbials: Erythromycin [124] Clarithromtcin [13]
Erythromycin [124]
Itraconazole [13]
Ketoconazole [13]
Miconazole [13]
Benzodiazepines: Alprazolam [13]
Diazepam [13]
Midazolam [13]
Triazolam [13]
Cardiac drugs: Digoxin* [88]
Quinidine [13]
Propranolol [13]
Verapamil [19]
Bupropion* [114]
Methadone [19]
Propranolol [13]
Warfarin* [113]
Propranolol [12] Nifedipine [13]
Propranolol [13]
Verapamil [19]
CNS drugs: Amitriptyline [125]
Bupropion [114]
Clomipramine [125]
Clozapine [19]
Amitriptyline [125]
Clomipramine [125]
Amitriptyline [119]
Clomipramine [119]
Phenytoin [120]
Clozapine [19]
Amitriptyline [125]
Buspirone [19]
Clomipramine [125]
Zolpidem [19]
Gastro-enterology 
drugs:
Ondansetron [19]
HIV Antivirals: Indinavir [13]
Nelfinavir [13]
Ritonavir [13]
Efavirenz [13] Nelfinavir [13] Nelfinavir [12] Amprenavir [13]
Delavirdine [13]
Indinavir [13]
Nelfinavir [13]
Nevirapine [13]
Ritonavir [13]
Saquinavir [13]
HMG CoA Reductase 
Inhibitors:
Fluvastatin [109]
Losartan [109]
Cerivastatin [103] Atorvastatin [109]
Cerivastatin [109]
Lovastatin [109]
Simvastatin * [108]
Hypoglycemics Pioglitazone [127] Glibenclamide [13]
Glipizide [13]
Nateglinide [13]
Rosiglitazone* [110]
Tolbutamine [13]
Repaglinide [12] Pioglitazone [127]
Immune Modulators: Cyclosporine [105]
Tacrolimus [17]
Methotrexate [19]
Cyclosporine* [105]
Sirolimus [17]
Tacrolimus [19]
Steroids: Cortisol [19]
Corticosterone [19]
Dexamethason [19]
Estradiol [19] Estradiol [19]
Ethinyloestradiol [19]
Hydrocortisone [19]Annals of Clinical Microbiology and Antimicrobials 2006, 5:3 http://www.ann-clinmicrob.com/content/5/1/3
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hepatocytes [97]. Thus, HNF4α is identified as the key
transcriptional factor for PXR. A specific cis-acting ele-
ment of gene enhancer in CYP3A4 has also identified
which confers HNF4α binding and permits PXR- and
CAR-mediated gene activation [22].
The molecular mechanisms that underlie transcriptional
activation of CYP3A4 are complex involving regulatory
factors other than PXR and CAR. These include glucocor-
ticoid and Vitamin D receptors. The CYP3A4 promoter
may also be regulated through mechanisms other than
PXR effects, including glucocorticoid-induced CYP3A4
gene expression, through the established PXR-dependent
pathway and a PXR-independent pathway [99]. Disrup-
tion of a responsive element in the CYP3A4 proximal pro-
moter for hepatocyte nuclear factor 3 and CCATT-
enhancer binding protein alpha affects its induction by
glucocorticoids, dexamethasone and hydrocortisone, but
not that by rifampicin. Vitamin D3 has also been shown
to induce CYP3A4 independently of PXR [100-102].
Explanation of drug-drug interactions
Some of the drugs affected by rifampicin are listed in
Table 1. Theoretically, any drugs or foods that affect the
activation or inhibition of PXR, and/or CYP3A4 and/or p-
glycoprotein will interact. CYP3A4 catalyse the metabo-
lism of more than 60% of all drugs currently in use includ-
ing contraceptive steroids, immunosuppressive agents,
imidazole antimycotics and macrolide antibiotics.
"Foods" such as grapefruit juice, black pepper inhibit
CYP3A4 so causing increased drug levels with resulting
therapeutic complications [89,103,104].
The drugs affected by or those that affect rifampicin have
been extensively reviewed elsewhere [6-11,13,14]. How-
ever, the mechanisms for these interactions are not well
studied, especially now that considerable progress has
been made in understanding the molecular mechanisms
of rifampicin. The following examples are selected to rep-
resent the major clinically significant rifampicin-inducing
drug-drug interactions mainly via the target genes
CYP3A4, CYP2C9, CYP2B6 and p-glycoprotein, and these
are labelled with * in Table 1.
Cyclosporine (CYP3A4)
Interaction of the immunosuppressant cyclosporine and
rifampicin is well documented. Doses of cyclosporine had
to be increased about 3 fold to maintain its therapeutic
blood concentration when coadministrated with
rifampicin [105]. A case report has shown that intrave-
nous rifampicin injection led to failure of bone marrow
transplantation resulting from subtherapeutic
cyclosporine blood levels [106].
Cyclosporine is mainly metabolized by CYP3A4 in
human liver [107]. Dexamethasone-induction of
cyclosporine metabolism is inhibited by anti-CYP3A4
antibodies in vitro and so it is quite likely that rifampicin-
inducing cyclosporine metabolism is mediated via
CYP3A4 although this has not yet been confirmed by in
vitro experiments [71].
Simvastatin (CYP3A4)
Simvastatin is used to treat hypercholesterolemia and is
metabolised to inactive metabolites by CYP3A4.
Rifampicin has been shown to reduce its effective concen-
tration while diltiazem, a CYP3A4 inhibitor increases its
concentration [108]. In healthy volunteers, 5 day pre-
treatment with rifampicin at a dose of 600 mg daily fol-
lowing a single 40 mg dose of simvastatin led to reduced
plasmid concentrations of simvastatin of 87 % compared
with the control [109]. Thus, concomitant administration
of rifampicin and simvastatin can lead to greatly reduced
cholesterol lowering efficiency of simvastatin.
Rosiglitazone (CYP2C9)
Rosiglitazone is a novel thiazolidinedione antidiabetic
drug. Its interaction with rifampicin has been studied in a
clinical trial [110]. When ten healthy subjects were
administered 8 mg of rosiglitazone after a 6 day pre-treat-
ment of rifampicin at a dose of 600 mg daily, rifampicin
decreased the plasma concentration of rosiglitazone by
65% and its elimination half-life from 3.9 to 1.5 hrs.
Because rosiglitazone is metabolised by CYP2C8 and
CYP2C9, it is proposed that the induction of these CYPs is
the basis for this interaction [110,111].
Warfarin (CYP2C9)
Warfarin is an anticoagulant drug metabolized by
CYP2C9 to 7-hydroxywarfarin [72,112]. Rifampicin
increases the rate of clearance of warfarin, thus reducing
its effect. In a patient receiving concomitant treatment
with rifamycin and warfarin, a 233% increase in warfarin
dosage over 4 months was insufficient to attain a thera-
peutic level and more aggressive upward titration of dose
was needed [14,13]. This may be the result of rifampicin
induced CYP2C9, which in turn accelerated warfarin
metabolism.
Bupropion (CYP2B6)
Bupropion, an antidepressant drug, is metabolized by
CYP2B6. Bupropion is hydroxylased by microsomes con-
taining cDNA-expressed CYP2B6 and the reaction is sub-
ject to 95% inhibition by CYP2B6 inhibitory antibody
[114]. High interdividual variability is thought to be a
consequence of interactions between environmental and
genetic influences on CYP2B6 gene function [115]. Thus,
rifampicin induction of CYP2B6 should lead to increasedAnnals of Clinical Microbiology and Antimicrobials 2006, 5:3 http://www.ann-clinmicrob.com/content/5/1/3
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bupropion metabolism, but no data are available to sup-
port this view.
Digoxin (p-glycoprotein)
Clinical observations have shown that digoxin serum con-
centration decreased considerably in patients who were
treated with rifampicin. This is of special interest since
digoxin is generally considered to be renally eliminated
[116,117]. In healthy volunteers, co-administration of
digoxin and rifampicin orally resulted in plasma concen-
tration of digoxin being much lower during rifampicin
treatment. However, the effect was less pronounced after
intravenous administration of digoxin [88].
The interaction is mainly mediated by p-glycoprotein in
the intestine and intestinal p-glycoprotein content
increased 3.5 fold on treatment with rifampicin, which
correlated with the decrease in its plasma concentration
after oral administration of digoxin [88]. Thus, induction
of p-glycoprotein could explain the rifampicin-digoxin
interaction.
Rifampicin-inducing hepatotoxicity
Rifampicin is very toxic to liver, this having been found
both in the treatment of tuberculosis and cholestasis
[128-130]. When it was used together with pyrazinamide,
a 5.8% incidence of severe liver injury was reported, 2.6%
with isoniazid and 1.1% alone [130]. The pathogenesis of
hepatotoxicity is poorly understood although limited evi-
dence has been obtained. Histopathological examination
showed dose-related hepatic necrosis, ballooning degen-
eration and inflammatory infiltratrates [130,131]. A pos-
sible explanation is the increased CYP related effects on
calcium homeostasis [132]. It may also be that via oxidant
stress, increased lipid peroxidation occurs [133]. In the
case when rifampicin and isoniazid are used together,
rifampicin may increase isoniazid toxicity though induc-
tion of CYPs because acetyl-isoniazid from isoniazid is
converted to monoacetyl hydrazine, which is catalysed by
CYPs to other hepato-toxic compounds. There were no
reports if nuclear receptors were involved in this patho-
genesis.
Conclusion
A common pattern for the molecular mechanisms of
rifampicin-inducing drug-drug interaction is rifampicin –
PXR/CAR – CYPs, UGTs, GSTs and p-glycoprotein. The
possible pathways for rifampicin effects on other drugs are
summarised in Table 1. However, other drugs may act in
a similar way to rifampicin, or by other pattern as seen
with dexamethasone. Therefore, how they act individually
is probably complex.
More studies are needed to further increase our knowl-
edge of rifampicin induced drug-drug interactions. Firstly,
aspects of the molecular mechanism including how
rifampicin activates PXR and modulates their binding to
the promoters of CYP3A4 and other target genes should
be explored. Secondly, the characterisation of drugs
affected by rifampicin and elucidation of their mecha-
nisms of interactions are urgently needed.
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